AUBURN, Ala., July 2, 2020 /PRNewswire/ -- SiO2 Materials Science, a privately-owned US-based advanced materials science company, today announced they have successfully scaled their manufacturing capacity ahead of schedule to 400 million doses and are on track to hit 1.2 billion capacity before the end of 2020. ...

Visit

FOR IMMEDIATE RELEASE

SiO2 Materials Science receives $143 million contract from U.S. Government to accelerate capacity scale-up of advanced primary packaging platform for COVID-19 Vaccines and Therapeutics

Company will add 200 high-skilled, manufacturing jobs

AUBURN, AL, June 8, 2020- SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, today announced a $143 million agreement with the federal government. The agreement with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) in partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), accelerates the production scale-up of the company’s state-of-the-art, patented, primary packaging platform for storing novel coronavirus (SARS-CoV-2) vaccines and therapeutics.

Read more ...

AUBURN, Ala. (PRWEB) April 29, 2020 SiO2 Materials Sciences launches a line of specialty vials for biological drugs and vaccines. The SiO2 vials solve significant challenges in the commercialization of vaccines and biological drugs which presently cannot be solved by glass or plastic vials. . . .

Visit

Auburn, Alabama, April 2020 – SiO2 Materials Science today announced the launch of a line of glass-alternative vials for use in vaccines, biological drugs, and cell & gene therapy primary packaging. ...

Download PDF

Auburn, Alabama, January 2020 – SiO2 Materials Science today announced that it has launched a new commercial organization to take the company to new heights. ...

Download PDF

AUBURN, Ala., Dec. 3, 2019 /PRNewswire/ -- SiO2 Materials Science is thrilled to launch the Synergy Tube, a proprietary Blood Collection Tube, as the company's first Genetic Diagnostics product on the market.

The Synergy Tube is a BCT specifically designed to optimize nucleic acid recovery and cancer tumor cells (CTC) from the point of blood draw. The Synergy Tube and proprietary stabilizer dramatically improve the quantity and quality of these components for downstream genetic diagnostics. . . .

Visit